Weekly Clinical Updates

Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection | The Importance of Understanding the Stages of COVID-19 in Treatment and Trials | Supratherapeutic tacrolimus concentrations with Nirmatrelvir/ritonavir in solid organ transplant recipients requiring hospitalization: A case series using rifampin for | Inflammasome activation in infected macrophages drives COVID-19 pathology | Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases | Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination

Effect of Early Treatment with Ivermectin among Patients with Covid-19 | Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission | Children and COVID-19: State Date Report | Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age | FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals | Recall of B cell memory depends on relative locations of prime and boost immunization | Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial

FDA Updates on Paxlovid for Health Care Providers | SARS-CoV-2 Omicron Variant is as Deadly as Previous Waves After Adjusting for Vaccinations, Demographics, and Comorbidities | Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine

Children and COVID-19: State Date Report | Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalization in the UK: a prospective observational study | Moderna files for authorization of Its COVID-19 Vaccine in young children six months to under six years of age | Public health impact of covid-19 vaccines in the US: observational study | FDA approves first COVID-19 Treatment for Young Children | Veru Announces Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region | Hospitalizations of Children Aged 5–11 Years with confirmed COVID | SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses | Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children | Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine | Low-dose bivalent mRNA vaccine is highly effective against different SARS-CoV-2 variants in a transgenic mouse model | Intramuscular AZD7442 for Prevention of Covid-19

Children and COVID-19: State Date Report | Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance | Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2 | Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination | Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization | Veru’s Novel COVID-19 Drug Candidate Reduces Deaths in Hospitalized Patients in Interim Analysis... | Comparison of Rapid Antigen Tests′ | SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies